2 global trials show mixed results for astegolimab for treating COPD
Genentech has announced mixed top-line results from two global clinical trials testing its treatment candidate astegolimab in people with moderate to very severe chronic obstructive pulmonary disease (COPD). Both one-year trials aimed to demonstrate that the therapy was superior to a placebo at reducing the annual rate of…